93.39
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALC Giù?
Forum
Previsione
Storia dei dividendi
Alcon Inc Borsa (ALC) Ultime notizie
Dry Eye Disease Market Growth in Future Scope 2025-2032 | - openPR.com
KeyBanc raises Alcon stock price target to $112 on growth outlook - Investing.com Canada
KeyBanc raises Alcon stock price target to $112 on growth outlook By Investing.com - Investing.com South Africa
3 Stocks to Watch in the Evolving Cell-Based Ophthalmic Therapy Space - TradingView
Deutsche Bank lifts Alcon stock price target to CHF96 from CHF92 - Investing.com Canada
Deutsche Bank lifts Alcon stock price target to CHF96 from CHF92 By Investing.com - Investing.com South Africa
Alcon Stock Might Rise as Clareon Vivity IOL Secures CE Mark Approval - MSN
Stifel maintains Alcon stock Buy rating, $100 target By Investing.com - Investing.com Australia
Citi maintains Alcon stock Buy rating, CHF99.00 target By Investing.com - Investing.com South Africa
Mizuho lifts Alcon stock price target to $120, maintains Outperform By Investing.com - Investing.com Canada
Taxation With Representation: Norton Rose, Latham, Ashurst - Law360
Oppenheimer Remains a Buy on Alcon (ALC) - The Globe and Mail
Alcon stock price target raised to $110 at Needham - Investing.com India
Alcon stock price target raised to $110 at Needham By Investing.com - Investing.com South Africa
Alcon (ALC) Soars 6.0%: Is Further Upside Left in the Stock? - Yahoo Finance
Mizuho lifts Alcon stock price target to $120, maintains Outperform - Investing.com
Jefferies raises Alcon stock price target to $115, maintains Buy - Investing.com India
Jefferies raises Alcon stock price target to $115, maintains Buy By Investing.com - Investing.com South Africa
Citi maintains Alcon stock Buy rating, CHF99.00 target - Investing.com India
Alcon (VTX:ALC) ascends 4.7% this week, taking five-year gains to 80% - Yahoo Finance
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Cell Therapy for Corneal Endothelial Disease - VisionMonday.com
Alcon Inc’s Acquisition of LENSAR Inc - Global Legal Chronicle
Alcon's Future Looks Fruitful as New Innovation and Commercial Execution Spark Market Outperformance - Morningstar
All eyes on ophthalmic cell therapy space as Alcon takes majority stake in Aurion - FirstWord Pharma
Alcon buys majority stake in IPO-seeking cell therapy startup Aurion - BioPharma Dive
Alcon claims control of cell therapy firm Aurion - pharmaphorum
Alcon acquires majority interest in Aurion Biotech - Ophthalmology Times
Alcon secures majority stake in Aurion, deposes CEO - PharmaLive
Related Content: Alcon to Acquire LENSAR | Business | Mar 2025 - Photonics Spectra
Alcon to buy Lensar in deal worth up to $430M - The Business Journals
Alcon to Acquire LENSAR | Business | Mar 2025 - Photonics.com
Alcon upgraded at BofA Securities to Buy on earnings growth potential - MSN
Alcon acquires majority interest in Aurion Biotech to advance first-ever corneal cell therapy candidate - BioSpectrum Asia
Aurion CEO is out as Alcon takes majority stake in cell therapy startup - Endpoints News
Alcon acquires majority stake in Aurion Biotech By Investing.com - Investing.com South Africa
Alcon buys majority stake in Aurion Biotech (ALC:NYSE) - Seeking Alpha
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease - Sharewise
Alcon acquires majority stake in Aurion Biotech - Investing.com
Alcon Acquires Majority Interest In Aurion Biotech, Inc. To Advance Innovative Cell Therapy For Corneal Endothelial Disease - MarketScreener
Alcon signs merger agreement to acquire Lensar - MSN
Stifel maintains Alcon stock Buy rating, $100 price target By Investing.com - Investing.com Australia
Stifel maintains Alcon stock Buy rating with $100 target By Investing.com - Investing.com Australia
Bernstein maintains Alcon Outperform rating, $110.50 target - Investing.com
Alcon lines up Lensar deal to expand laser cataract surgery options - Optics.org
Alcon Gets EU Nod for Clareon Vivity Intraocular Lens - MPO-mag
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):